Core Insights - Syndax Pharmaceuticals announced that revumenib has been included as a category 2A recommendation in the NCCN Guidelines for relapsed or refractory acute myeloid leukemia (AML) with an NPM1 mutation, highlighting the drug's clinical significance [1][2] - The company has submitted a supplemental New Drug Application (sNDA) for revumenib, which has been granted Priority Review by the FDA, with a target action date of October 25, 2025 [2][6] Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies, with revumenib being a first-in-class menin inhibitor approved for certain types of acute leukemia [5][23] - The company is actively conducting multiple clinical trials to explore revumenib's efficacy in various treatment settings, including combinations with standard therapies for newly diagnosed patients [7][24] Industry Context - The NCCN is a not-for-profit alliance of 33 leading cancer centers that develops clinical practice guidelines to inform treatment decisions for healthcare stakeholders [3] - Mutant NPM1 (mNPM1) AML is a prevalent genetic alteration in AML, affecting approximately 30% of adult patients, and is associated with a poor prognosis and high relapse rates [4]